ACR

557: The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Ef ...

2558: Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizuma ...

4M027: The Year in Review: Update on Safety Issues at the FDA Over the Last 12 Months. Reumatoloog P ...

2693: What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Sys ...

2468: Window or No Window? Earlier Is Better When Treating Rheumatoid Arthritis. Download hier de Po ...

L17: Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results ...

2248: Genetic Variants Identify Interleukin 37 As an Important Anti-Inflammatory Cytokine in Gout in ...

2565: Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patient ...

2785: Efficacy and Safety of Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Sy ...

1519: Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rh ...

2788: The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-Induction for ...

2077: Pathological Osteogenesis and Inflammation in Experimental Spondyloarthritis Are Associated wi ...

2924: Spinal Radiographic Progression in Early Axial Spondyloarthritis: 5-Year Data from the DESIR C ...

835: Identifying Individuals with High Risk for Imminent Onset of Rheumatoid Arthritis. Simone Vreug ...

2826: Emergence of Severe Spondyloarthropathy Related Entheseal Pathology Following Successful Vedol ...

2241: What Can Variation in Clinical Practice Teach Us about Treatment Strategies for Patients with ...

2586: Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic A ...

PA4001: Dynamic hyperinflation predicts impaired daily life activity in asthma. Longarts Akke-Nynke ...